RecruitingType 2 Diabetes Mellitus
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening
- ✓ Have an HbA1c ≥7% and ≤10.5% at screening
- ✓ Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
- ✓ Body mass index (BMI) ≥23.0 kg/m\^2 at screening
- ✓ A stable body weight within 3 months prior to screening (maximum 5% self-reported body weight gain and/or loss)
You may not qualify if…
- ✕ Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D
- ✕ Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening
- ✕ History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment
- ✕ Evidence of clinically significant/active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea)
- ✕ Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors
- ✕ Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome)
- ✕ Have a known, clinically significant gastric emptying abnormality
- ✕ Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension
Where it's recruiting
Arizona
Tucson
California
Lake Forest · Rancho Cucamonga · Spring Valley
Connecticut
Waterbury
District of Columbia
Washington D.C.
Florida
Clermont · Pembroke Pines
Georgia
Union City
Illinois
Oak Lawn
Montana
Butte
New York
Cedarhurst
North Carolina
Statesville · Wilmington
Ohio
Lima
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT07112872 · last updated 2026-11-12